NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 10/22/2025 at 14:45, 9 months 23 days ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action

NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
BRIEF

published on 10/20/2025 at 14:50, 9 months 25 days ago

NanoViricides annonce un traitement prometteur contre la rougeole

NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Utilisation D'urgence
BRIEF

published on 10/20/2025 at 14:50, 9 months 25 days ago

NanoViricides Announces Promising Measles Treatment

NanoViricides NV-387 Antiviral Drug Measles Treatment Emergency Use
PRESS RELEASE

published on 10/20/2025 at 14:45, 9 months 25 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I
BRIEF

published on 10/15/2025 at 14:50, 9 months 30 days ago

NanoViricides poursuit une stratégie clinique à double voie pour le NV-387

Antiviral À Large Spectre Essais De Phase II Développement NV-387 Essai MPox Virus Respiratoires
BRIEF

published on 10/15/2025 at 14:50, 9 months 30 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
PRESS RELEASE

published on 10/15/2025 at 14:45, 9 months 30 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 10 months 14 days ago

Progrès du NV-387 de NanoViricides dans les essais cliniques

NanoViricides NV-387 Essais Cliniques Thérapie Antivirale Défis De Financement
BRIEF

published on 09/30/2025 at 14:50, 10 months 14 days ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
PRESS RELEASE

published on 09/30/2025 at 14:45, 10 months 14 days ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral

Published on 08/15/2026 at 00:50, 9 hours 27 minutes ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 10 hours 2 minutes ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 10 hours 32 minutes ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 10 hours 52 minutes ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 11 hours 17 minutes ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

Published on 08/15/2026 at 08:05, 2 hours 12 minutes ago

SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:29, 15 hours 48 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 15 hours 48 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 16 hours 2 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 18 hours 12 minutes ago

GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON

View all EQS

Published on 08/13/2026 at 18:00, 1 day 16 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 16 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 16 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 16 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 16 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE

News